Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guanglei Yu

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Journal of Crohn'S & Colitis|June 10, 2025
Impact of mirikizumab treatment on fatigue in patients with moderately to severely active Crohn's disease: results from the phase 3 VIVID-1 studyMiguel Regueiro, Monika Fischer, Peter Bossuyt, et al.
Journal of Crohn'S & Colitis|June 17, 2026
Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial resultsVipul Jairath, Fernando Magro, Marijana Protic, et al.
The New England Journal of Medicine|March 25, 2022
Two Phase 3 Trials of Baricitinib for Alopecia AreataBrett King, Manabu Ohyama, Ohsang Kwon, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 7, 2026
Mirikizumab Long-Term Efficacy and Safety in Patients with Crohn's disease: Results from the VIVID-2 Open-Label Extension TrialBruce E Sands, Edward L Barnes, Geert D'Haens, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 16, 2025
Bowel Urgency in Crohn's Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 StudyVipul Jairath, Geert D'Haens, Bruce E Sands, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Journal of Crohn'S & Colitis|June 10, 2025
Impact of mirikizumab treatment on fatigue in patients with moderately to severely active Crohn's disease: results from the phase 3 VIVID-1 studyMiguel Regueiro, Monika Fischer, Peter Bossuyt, et al.
Journal of Crohn'S & Colitis|June 17, 2026
Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial resultsVipul Jairath, Fernando Magro, Marijana Protic, et al.
The New England Journal of Medicine|March 25, 2022
Two Phase 3 Trials of Baricitinib for Alopecia AreataBrett King, Manabu Ohyama, Ohsang Kwon, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 7, 2026
Mirikizumab Long-Term Efficacy and Safety in Patients with Crohn's disease: Results from the VIVID-2 Open-Label Extension TrialBruce E Sands, Edward L Barnes, Geert D'Haens, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 16, 2025
Bowel Urgency in Crohn's Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 StudyVipul Jairath, Geert D'Haens, Bruce E Sands, et al.
Pageof 4